Historically, the AMPK protein was viewed as a tumor inhibitor because of its ability to inhibit the mTORC1 signaling pathway through the phosphorylation of TSC2 and RAPTOR, which are pathways that are often associated with carcinogenesis [37]. Here, RPTOR is linked to neoplasm.